# Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

> **NCT03782792** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 53 (actual)

## Conditions studied

- Generalized Pustular Psoriasis

## Interventions

- **DRUG:** Spesolimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03782792
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-31
- **Primary completion:** 2020-09-23
- **Final completion:** 2021-01-05
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03782792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03782792, "Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03782792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*